Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level.
暂无分享,去创建一个
N. Santos | S. Henriques | M. Castanho | Nuno C Santos | Miguel Castanho | Salomé Veiga | Sónia Henriques | Salomé Veiga
[1] E Jakobsson,et al. Combined Monte Carlo and molecular dynamics simulation of fully hydrated dioleyl and palmitoyl-oleyl phosphatidylcholine lipid bilayers. , 1999, Biophysical journal.
[2] Manuel Prieto,et al. Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods. , 2003, Biochimica et biophysica acta.
[3] L. Mayer,et al. Vesicles of variable sizes produced by a rapid extrusion procedure. , 1986, Biochimica et biophysica acta.
[4] Robert B. Gennis,et al. Biomembranes: Molecular Structure and Function , 1988 .
[5] M. Prieto,et al. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. , 1998, Biochemistry.
[6] Luís M. S. Loura,et al. Resonance energy transfer in a model system of membranes: application to gel and liquid crystalline phases. , 1996, Biophysical journal.
[7] J. García de la Torre,et al. Joint determination by Brownian dynamics and fluorescence quenching of the in-depth location profile of biomolecules in membranes. , 2002, Analytical biochemistry.
[8] S. A. Gallo,et al. Mode of Action of an Antiviral Peptide from HIV-1 , 2001, The Journal of Biological Chemistry.
[9] J. Seelig,et al. Isothermal titration calorimetry for studying interactions between peptides and lipid membranes , 2002 .
[10] Stephen C. Blacklow,et al. A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.
[11] E. Müller. Biomembranes, R.B. Gennis, in: Molecular Structure and Function. Series: Springer Advanced Texts in Chemistry, 533 S.. Springer-Verlag, New York-Berlin-Heidelberg-London-Paris-Tokyo (1989), 142 Abb., zahlr. Tab. Preis: DM 98. , 1990 .
[12] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[13] A. Debnath,et al. Peptide and non-peptide HIV fusion inhibitors. , 2002, Current pharmaceutical design.